LUMPO

LUMPO brings together the clinical, pathological and genetic features of an individual uveal melanoma to estimate that patient's risk of metastatic disease over time. It is used by ocular oncology centres worldwide to inform surveillance and to guide entry into clinical trials.

What LUMPO does

Uveal melanoma is the most common primary eye cancer in adults, and its outlook varies widely from one person to the next. By combining factors such as patient age and sex, tumour size and location, cell type, and molecular markers including chromosome 3 and BAP1 status, LUMPO produces an individualised survival estimate rather than a single population average.

The result helps clinical teams tailor how closely a patient is monitored after treatment, and supports informed conversations about prognosis. It draws on more than two decades of research and outcome data from the group and its collaborators.

Who it is for

LUMPO is a decision-support tool intended for clinicians and researchers. Its estimates should always be interpreted by a qualified professional in the context of the full clinical picture, and are not a substitute for individual medical advice.

How it works

The tool is developed and hosted by the University of Liverpool, with the underlying statistical model maintained by the group's mathematical and statistical modelling team. It has been externally validated across multiple international centres, and continues to be refined as new evidence emerges.

Key references

• Czarnecki HD, Edwards A, Kalirai H, Afshar RN, Damato BE, Heimann H, Coupland SE (2025). Monosomy 3 prediction by clinical features and BAP1 staining and its value when integrated in the Liverpool Uveal Melanoma Prognosticator Online (LUMPO3). Investigative Ophthalmology & Visual Science.
• Damato B, Eleuteri A, Taktak A, Hussain R, Fili M, Stålhammar G, Heimann H, Coupland SE (2024). Deferral of treatment for small choroidal melanoma and the risk of metastasis: an investigation using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO). Cancers.
• Eleuteri A, Cunha Rola A, Kalirai H, Hussain R, Sacco J, Damato BE, Heimann H, Coupland SE, Taktak AFG (2021). Cost-utility analysis of a decade of liver screening for metastases using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO). Computers in Biology and Medicine.
• Cunha Rola A, Taktak A, Eleuteri A, Kalirai H, Heimann H, Hussain R, et al. (2020). Multicenter external validation of the Liverpool Uveal Melanoma Prognosticator Online: an OOG collaborative study. Cancers (Basel).

See the group's full publications list for further work on uveal melanoma prognostication.